Оksana S. Fuks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Оksana S. Fuks has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana Leonidovna Karonova
Almazov National Medical Research Center
10 shared publications - Natalya V. Timkina
Almazov National Medical Research Centre
9 shared publications - Anna Vladimirovna Simanenkova
Almazov National Medical Research Centre
6 shared publications - Timur D. Vlasov
Pavlov First Saint Petersburg State Medical University
5 shared publications - Arina Alekseevna Mikhailova
Almazov National Medical Research Centre
3 shared publications A. V. Murasheva
Almazov National Medical Research Centre
2 shared publications
Latest Publications
- Open Access
- 23 May 2025
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (2) , 187-197
Comparative evaluation of SGLT-2i and GLP-1RA neuroprotective properties in type 2 diabetic patients
BACKGROUND: Chronic brain dyscirculation (CBD) is a common type 2 diabetes mellitus (DM) complication that leads to the cognitive dysfunction. Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter type 2 inhibitors (SGLT-2i) can reduce the stroke risk but their effect on CBD is not fully studied.AIM: To study and to compare the effect of SGLT-2i of various selectivity and GLP-1RA on the biochemical and functional parameters of CNS damage in patients with type 2 DM.MATERIALS AND METHODS: Type 2 diabetic patients with target HbA1c level on metformin monotherapy were included in “MET” group (n=43), with non-target HbA1c were divided into groups: “MET+EMPA”, n=47, (empagliflozin therapy), “MET+CANA”, n=41, (canagliflozin therapy), “MET+GLP-1RA”, n=66 (therapy with injectable GLP-1RA). The “Control” group (n=23) consisted of healthy volunteers. In “Control” and “MET” groups at baseline, in the rest groups also after 3 and 6 months neuron-specific enolase (NSE), neurofilament light chains (NLC) levels and cognitive status were determined.RESULTS: NSE was increased in all DM patients. GLP-1RA therapy did not lead to NSE decrease. NSE decreased in “MET+EMPA” group after 3 months and in “MET+CANA” group after 6 months. NLC levels were elevated in patients with non-target HbA1c compared to “Control”. Both SGLT-2i caused a more pronounced decrease in LCN than GLP-1RA after 3 months; after 6 months NLC in all treatment groups did not differ from “Control” group. At baseline all DM patients had impaired cognitive function according to MOCA and MMSE. Empagliflozin treatment resulted in the improvement, but not normalization, of cognitive status by MOCA scale. Canagliflozin led to cognitive function normalization after 3 months and retention of the effect. GLP-1RA use was associated with mental function normalization after 6 months. Satisfactory glycemic control was achieved in all groups.CONCLUSION: Type 2 DM is characterized by CNS damage even with satisfactory glycemic control. GLP-1RA and SGLT-2i have a protective effect in CBD in DM; the protective potential of low-selective canagliflozin is probably more pronounced, as it manifests in biochemical and functional parameters improvement. The neurotropic effect of GLP-1RA and SGLT-2i is not due solely to their effect on the glycemic profile.
- 23 May 2025
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (2) , 187-197
Open AccessComparative evaluation of SGLT-2i and GLP-1RA neuroprotective properties in type 2 diabetic patients
BACKGROUND: Chronic brain dyscirculation (CBD) is a common type 2 diabetes mellitus (DM) complication that leads to the cognitive dysfunction. Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter type 2 inhibitors (SGLT-2i) can reduce the stroke risk but their effect on CBD is not fully studied.AIM: To study and to compare the effect of SGLT-2i of various selectivity and GLP-1RA on the biochemical and functional parameters of CNS damage in patients with type 2 DM.MATERIALS AND METHODS: Type 2 diabetic patients with target HbA1c level on metformin monotherapy were included in “MET” group (n=43), with non-target HbA1c were divided into groups: “MET+EMPA”, n=47, (empagliflozin therapy), “MET+CANA”, n=41, (canagliflozin therapy), “MET+GLP-1RA”, n=66 (therapy with injectable GLP-1RA). The “Control” group (n=23) consisted of healthy volunteers. In “Control” and “MET” groups at baseline, in the rest groups also after 3 and 6 months neuron-specific enolase (NSE), neurofilament light chains (NLC) levels and cognitive status were determined.RESULTS: NSE was increased in all DM patients. GLP-1RA therapy did not lead to NSE decrease. NSE decreased in “MET+EMPA” group after 3 months and in “MET+CANA” group after 6 months. NLC levels were elevated in patients with non-target HbA1c compared to “Control”. Both SGLT-2i caused a more pronounced decrease in LCN than GLP-1RA after 3 months; after 6 months NLC in all treatment groups did not differ from “Control” group. At baseline all DM patients had impaired cognitive function according to MOCA and MMSE. Empagliflozin treatment resulted in the improvement, but not normalization, of cognitive status by MOCA scale. Canagliflozin led to cognitive function normalization after 3 months and retention of the effect. GLP-1RA use was associated with mental function normalization after 6 months. Satisfactory glycemic control was achieved in all groups.CONCLUSION: Type 2 DM is characterized by CNS damage even with satisfactory glycemic control. GLP-1RA and SGLT-2i have a protective effect in CBD in DM; the protective potential of low-selective canagliflozin is probably more pronounced, as it manifests in biochemical and functional parameters improvement. The neurotropic effect of GLP-1RA and SGLT-2i is not due solely to their effect on the glycemic profile.
- Open Access
- 21 January 2025
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 30 (5) , 441-450
Fibroblast growth factor 21: a novel link in the development and treatment of metabolic disorders
In recent years, fibroblast growth factor 21 (FGF21) has garnered increasing attention as a metabolic regulator. It plays a role in the development of tissue insulin sensitivity, exerts beneficial effects on carbohydrate and lipid metabolism, and exhibits antihyperglycemic and antilipidemic properties. Elevated FGF21 levels have been observed in patients with type 2 diabetes, obesity, non-alcoholic fatty liver disease, and a range of other conditions. This may indicate either resistance to FGF21 or a compensatory response to metabolic stress. Evidence suggests that FGF21 can be considered both a marker of several metabolic disorders and a potential therapeutic agent for the treatment of significant societal health issues. Objective. The objective of this review is to summarize the data published to date in the literature, including meta-analyses, reviews, and original studies, focusing on the diagnostic and potential therapeutic role of FGF21 in metabolic disorders.
- 21 January 2025
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 30 (5) , 441-450
Open AccessFibroblast growth factor 21: a novel link in the development and treatment of metabolic disorders
In recent years, fibroblast growth factor 21 (FGF21) has garnered increasing attention as a metabolic regulator. It plays a role in the development of tissue insulin sensitivity, exerts beneficial effects on carbohydrate and lipid metabolism, and exhibits antihyperglycemic and antilipidemic properties. Elevated FGF21 levels have been observed in patients with type 2 diabetes, obesity, non-alcoholic fatty liver disease, and a range of other conditions. This may indicate either resistance to FGF21 or a compensatory response to metabolic stress. Evidence suggests that FGF21 can be considered both a marker of several metabolic disorders and a potential therapeutic agent for the treatment of significant societal health issues. Objective. The objective of this review is to summarize the data published to date in the literature, including meta-analyses, reviews, and original studies, focusing on the diagnostic and potential therapeutic role of FGF21 in metabolic disorders.
- Open Access
- 10 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12)
SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
Background: SGLT-2 inhibitors (SGLT-2i) and GLP-1 receptor agonists (GLP-1RA) have demonstrated nephro- and cardioprotective effects, but their neuroprotective properties, especially concerning stroke severity, and mechanisms are not unambiguous. We aimed to study the influence of SGLT-2i with different selectivity and GLP-1RA on brain damage volume and neurological status in non-diabetic and diabetic rats and to investigate the underlying mechanisms. Methods: Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug. Control animals were administered 0.9% NaCl for 7 days before stroke. At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume. We also modeled type 2 DM in Wistar rats using the high-fat diet+nicotinamide/streptozotocin method and established similar treatment groups. After 8 weeks, rats were subjected to stroke with further neurological deficit, neuroglial damage markers, and brain necrosis volume measurement. Results: In non-diabetic rats, all the drugs showed an infarct-limiting effect; SGLT-2i and dulaglutide were more effective than metformin. DULA improved neurological status compared with MET and SGLT-2i treatment. All the drugs decreased neurofilament light chains (NLCs) level and neuronal damage markers, but none of them decreased the glial damage marker S100BB. In DM, similarly, all the drugs had infarct-limiting effects. Neurological deficit was most pronounced in the untreated diabetic rats and was reduced by all study drugs. All the drugs reduced NLC level; dulaglutide and empagliflozin, but not canagliflozin, also decreased S100BB. None of the drugs affected neuron-specific enolase. Conclusions: SGLT-2i and GLP-1RA are neuroprotective in experimental stroke. GLP-1RA might be more effective than SGLT-2i as in non-diabetic conditions it influences both brain damage volume and neurological status. All study drugs decrease neuronal damage, while GLP-1RA and highly selective SGLT-2i EMPA, but not low-selective CANA, also have an impact on neuroglia in diabetic conditions.
- 10 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12)
Open AccessSGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
Background: SGLT-2 inhibitors (SGLT-2i) and GLP-1 receptor agonists (GLP-1RA) have demonstrated nephro- and cardioprotective effects, but their neuroprotective properties, especially concerning stroke severity, and mechanisms are not unambiguous. We aimed to study the influence of SGLT-2i with different selectivity and GLP-1RA on brain damage volume and neurological status in non-diabetic and diabetic rats and to investigate the underlying mechanisms. Methods: Non-diabetic Wistar rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug. Control animals were administered 0.9% NaCl for 7 days before stroke. At 48 h after stroke, we assessed neurological deficit, neuronal and astroglial damage markers, and brain damage volume. We also modeled type 2 DM in Wistar rats using the high-fat diet+nicotinamide/streptozotocin method and established similar treatment groups. After 8 weeks, rats were subjected to stroke with further neurological deficit, neuroglial damage markers, and brain necrosis volume measurement. Results: In non-diabetic rats, all the drugs showed an infarct-limiting effect; SGLT-2i and dulaglutide were more effective than metformin. DULA improved neurological status compared with MET and SGLT-2i treatment. All the drugs decreased neurofilament light chains (NLCs) level and neuronal damage markers, but none of them decreased the glial damage marker S100BB. In DM, similarly, all the drugs had infarct-limiting effects. Neurological deficit was most pronounced in the untreated diabetic rats and was reduced by all study drugs. All the drugs reduced NLC level; dulaglutide and empagliflozin, but not canagliflozin, also decreased S100BB. None of the drugs affected neuron-specific enolase. Conclusions: SGLT-2i and GLP-1RA are neuroprotective in experimental stroke. GLP-1RA might be more effective than SGLT-2i as in non-diabetic conditions it influences both brain damage volume and neurological status. All study drugs decrease neuronal damage, while GLP-1RA and highly selective SGLT-2i EMPA, but not low-selective CANA, also have an impact on neuroglia in diabetic conditions.
- Open Access
- 1 November 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 163-170
Comparative study of the neuroprotective potential of semaglutide injectable preparations in experimental ischemic stroke
Introduction. Stroke remains one of the major causes of death in type diabetes mellitus (DM). Injectable form of glucagon-like peptide-1 receptor agonist semaglutide, Ozempic® decreases the stroke risk. In Russia there appeared a biosimilar Semavic® but its effects on the brain are not yet studied.Aim. To compare neuroprotective properties of Semavic® and Ozempic® while used before ischemic stroke in rats without DM.Materials and methods. The study was conducted in male Wistar rats that were divided into the following groups: “Control” (n = 10) – 0.9% NaCl, “MET” (n = 9) – metformin 200 mg/kg once daily per os, “Ozempic” (n = 10) – Ozempic® 0.012 mg/kg s.c. once daily, “Semavic” (n = 9) – Semavic® 0.012 mg/kg s.c. once daily. After 7 days ischemic stroke was modelled, after 48 hour of reperfusion neurological deficit and brain damage volume were evaluated. Glycemia was measured on the 3rd, 7th days as well as during and after ischemia.Results. None of the study drugs caused hypoglycemia including in poststroke period. Neurological deficit in “MET” group did not differ from that in the “Control” (11.00 [6.50; 12.50] and 10.0 [6.25; 12.00] scores). Both semaglutide drugs caused comparable improvement in neurological status (14.00 [12.00; 18.00] and 14.00 [11.00; 18.00] scores in “Ozempic” and “Semavic” groups). Brain necrosis volume in “Control” group was 16.60 [13.40; 28.58] %. All the study drugs had infarct-limiting effect but brain damage volume in “Ozempic” (6.00 [4.32; 8.44] %) and “Semavic” (7.69 [2.99; 11.33] %) was smaller than in “MET” group (13.07 [8.67; 29.94] %). There were no differences between semaglutide drugs.Conclusions. Biosimilar Semavic® and original Ozempic® demonstrate comparable neuroprotective effect while used in animals without DM prior to ischemic stroke modelling. This protective effect is not due to the drugs’ influence on glycemic profile.
- 1 November 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 163-170
Open AccessComparative study of the neuroprotective potential of semaglutide injectable preparations in experimental ischemic stroke
Introduction. Stroke remains one of the major causes of death in type diabetes mellitus (DM). Injectable form of glucagon-like peptide-1 receptor agonist semaglutide, Ozempic® decreases the stroke risk. In Russia there appeared a biosimilar Semavic® but its effects on the brain are not yet studied.Aim. To compare neuroprotective properties of Semavic® and Ozempic® while used before ischemic stroke in rats without DM.Materials and methods. The study was conducted in male Wistar rats that were divided into the following groups: “Control” (n = 10) – 0.9% NaCl, “MET” (n = 9) – metformin 200 mg/kg once daily per os, “Ozempic” (n = 10) – Ozempic® 0.012 mg/kg s.c. once daily, “Semavic” (n = 9) – Semavic® 0.012 mg/kg s.c. once daily. After 7 days ischemic stroke was modelled, after 48 hour of reperfusion neurological deficit and brain damage volume were evaluated. Glycemia was measured on the 3rd, 7th days as well as during and after ischemia.Results. None of the study drugs caused hypoglycemia including in poststroke period. Neurological deficit in “MET” group did not differ from that in the “Control” (11.00 [6.50; 12.50] and 10.0 [6.25; 12.00] scores). Both semaglutide drugs caused comparable improvement in neurological status (14.00 [12.00; 18.00] and 14.00 [11.00; 18.00] scores in “Ozempic” and “Semavic” groups). Brain necrosis volume in “Control” group was 16.60 [13.40; 28.58] %. All the study drugs had infarct-limiting effect but brain damage volume in “Ozempic” (6.00 [4.32; 8.44] %) and “Semavic” (7.69 [2.99; 11.33] %) was smaller than in “MET” group (13.07 [8.67; 29.94] %). There were no differences between semaglutide drugs.Conclusions. Biosimilar Semavic® and original Ozempic® demonstrate comparable neuroprotective effect while used in animals without DM prior to ischemic stroke modelling. This protective effect is not due to the drugs’ influence on glycemic profile.
- Open Access
- 15 September 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 70 (4) , 44-56
Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation
BACKGROUND: Chronic brain dyscirculation is one of the frequent type 2 diabetes mellitus (DM) complications and leads to patients’ disability. Sodium-glucose co-transporter type 2 inhibitors (SGLT-2i) have been proven to have advantages for cardiovascular system, but their effect on the central nervous system (CNS) has not been studied enough.AIM: To study empagliflozin effect on CNS damage functional and laboratory parameters in patients with type 2 DM and, under experimental conditions, to investigate the mechanisms of the drug neurotropic effect.MATERIALS AND METHODS: The clinical part of the study included patients with type 2 DM on metformin monotherapy (n=39). Patients with a target glycated hemoglobin level formed the “MET” group (n=19), in patients with a non-target glycated hemoglobin level empagliflozin was co-administered for the following 6 months (the “MET+EMPA” group, n=20). Healthy volunteers comprised the control group (n=16). The cognitive status and neuron-specific enolase (NSE) and neurofilament light chains (NLC) concentration were studied. DM was modeled in rats, thereafter the rats were treated with empagliflozin for 8 weeks. Microglia activation was assessed using anti-Iba-1 antibodies and morphological changes in neurons when stained by the Nissl method.RESULTS: Both in the “MET+EMPA” and the “MET” groups cognitive deficits were observed, according to the Montreal Cognitive Assessment (MOCA) (24.0 (23.0; 27.0) and 25.0 (21.0; 27.0) points) and the Mini-Mental State Examination (MMSE) (23.75 (23.0; 27.0) and 25.0 (21.0; 27.0) points). Empagliflozin therapy led to the cognitive status normalization after 6 months (26.5 (24.0; 27.0) points according to the MOCA scale and 27.5 (24.0; 28.0) points according to the MMSE). Initially, all patients had a significant increase of NSE (3.60 (2.66; 3.76) ng/ml in the “MET” group, 3.22 (2.94; 3.54) ng/ml in the “MET+EMPA» group, 2.72 (2.13; 2.72) ng/ml in the «Control» group) and NLC (4.50 (3.31; 5.56) ng/ml in the «MET» group, 5, 25 (3.75; 6.25) ng/ml in the «MET+EMPA» group comparing with 3.50 (2.25; 3.50) ng/ml in the «Control» group). Empagliflozin therapy led to a significant decrease in NLC already after 3 months (3.80 (3.25; 3.87) ng/ml), without significant influence on the NSE level. In the experiment, DM was characterized by an increased number of activated microgliocytes and destructured neurons and a decreased number of neurons with a normal structure. Empagliflozin therapy was accompanied by a decrease in the number of immunopositive microgliocytes in the CA1 zone of the hippocampus and an increase in the number of structured neurons.CONCLUSION: Type 2 diabetes mellitus is characterized by functional and biochemical changes in the central nervous system even under satisfactory glycemic control. Therapy with empagliflozin has a neuroprotective effect, manifested in an improvement in cognitive status and a decrease in NLC level. Empagliflozin reduces neuronal damage and abnormal microglial activation.
- 15 September 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 70 (4) , 44-56
Open AccessHighly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation
BACKGROUND: Chronic brain dyscirculation is one of the frequent type 2 diabetes mellitus (DM) complications and leads to patients’ disability. Sodium-glucose co-transporter type 2 inhibitors (SGLT-2i) have been proven to have advantages for cardiovascular system, but their effect on the central nervous system (CNS) has not been studied enough.AIM: To study empagliflozin effect on CNS damage functional and laboratory parameters in patients with type 2 DM and, under experimental conditions, to investigate the mechanisms of the drug neurotropic effect.MATERIALS AND METHODS: The clinical part of the study included patients with type 2 DM on metformin monotherapy (n=39). Patients with a target glycated hemoglobin level formed the “MET” group (n=19), in patients with a non-target glycated hemoglobin level empagliflozin was co-administered for the following 6 months (the “MET+EMPA” group, n=20). Healthy volunteers comprised the control group (n=16). The cognitive status and neuron-specific enolase (NSE) and neurofilament light chains (NLC) concentration were studied. DM was modeled in rats, thereafter the rats were treated with empagliflozin for 8 weeks. Microglia activation was assessed using anti-Iba-1 antibodies and morphological changes in neurons when stained by the Nissl method.RESULTS: Both in the “MET+EMPA” and the “MET” groups cognitive deficits were observed, according to the Montreal Cognitive Assessment (MOCA) (24.0 (23.0; 27.0) and 25.0 (21.0; 27.0) points) and the Mini-Mental State Examination (MMSE) (23.75 (23.0; 27.0) and 25.0 (21.0; 27.0) points). Empagliflozin therapy led to the cognitive status normalization after 6 months (26.5 (24.0; 27.0) points according to the MOCA scale and 27.5 (24.0; 28.0) points according to the MMSE). Initially, all patients had a significant increase of NSE (3.60 (2.66; 3.76) ng/ml in the “MET” group, 3.22 (2.94; 3.54) ng/ml in the “MET+EMPA» group, 2.72 (2.13; 2.72) ng/ml in the «Control» group) and NLC (4.50 (3.31; 5.56) ng/ml in the «MET» group, 5, 25 (3.75; 6.25) ng/ml in the «MET+EMPA» group comparing with 3.50 (2.25; 3.50) ng/ml in the «Control» group). Empagliflozin therapy led to a significant decrease in NLC already after 3 months (3.80 (3.25; 3.87) ng/ml), without significant influence on the NSE level. In the experiment, DM was characterized by an increased number of activated microgliocytes and destructured neurons and a decreased number of neurons with a normal structure. Empagliflozin therapy was accompanied by a decrease in the number of immunopositive microgliocytes in the CA1 zone of the hippocampus and an increase in the number of structured neurons.CONCLUSION: Type 2 diabetes mellitus is characterized by functional and biochemical changes in the central nervous system even under satisfactory glycemic control. Therapy with empagliflozin has a neuroprotective effect, manifested in an improvement in cognitive status and a decrease in NLC level. Empagliflozin reduces neuronal damage and abnormal microglial activation.
- Open Access
- 24 July 2024
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 29 (7) , 265
Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i
Background: Acute and chronic brain damage in type 2 diabetes mellitus (DM) determines the need to investigate the neuroprotective potential of glucose-lowering drugs. The purpose was to directly compare the neuroprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) with different duration of action and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in type 2 diabetic rats with and without stroke. Methods: DM was modelled using high-fat diet and nicotinamide+streptozotocin protocol. The following groups (n = 15 each) were formed: DM without treatment, treatment with liraglutide, dulaglutide, canagliflozin as well as control group without DM and treatment. After 8 weeks, 10 rats from each group underwent middle cerebral artery occlusion. In the reperfusion period neurological deficit, neuroglial damage markers and brain necrosis were evaluated. Brain slices from the remaining 5 animals in each group were histologically examined for microglial activation and neuronal damage. Results: Brain damage was similar in “DM” and “Control” (17.53 [14.23; 26.58] and 15.87 [13.40; 22.68] % of total brain volume, respectively). All study drugs diminished damage volume comparing with “DM” and “Control” whereas the necrosis volume in “DM+Liraglutide” was smaller than in “DM+Canagliflozin” and did not significantly differ from “DM+Dulaglutide” (2.9 [1.83; 4.71], 6.17 [3.88; 8.88] and 4.57 [3.27; 7.90] %). The neurological deficit was more prominent in “DM” than in “Control”, while all the drugs demonstrated similar positive effect. Neurofilament light chains (NLC) did not differ between “DM” and “Control”. Dulaglutide and canagliflozin caused a marked decrease in NLC. Protein S100BB level was similar in “DM” and “Control”. Liraglutide caused the largest S100BB decrease, while canagliflozin did not influence it. In chronic brain ischaemia, all drugs increased the number of normal neurons, but GLP-1RAs had a more pronounced effect. DM was accompanied by increased number of activated microglial cells in Cornu Ammonis (CA)1 hippocampal region. Both GLP-1RAs reduced the number of Iba-1-positive cells, with dulaglutide being more effective than liraglutide, whereas canagliflozin did not affect this parameter. Conclusions: GLP-1RAs and SGLT-2i have neuroprotective properties against acute and chronic brain damage in diabetic rats, although the infarct-limiting effect of GLP-1RAs may be more pronounced. GLP-1RAs and SGLT-2i exert their protective effects by directly influencing neuronal survival, whereas GLP-1RAs also affect microglia.
- 24 July 2024
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 29 (7) , 265
Open AccessMicroglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i
Background: Acute and chronic brain damage in type 2 diabetes mellitus (DM) determines the need to investigate the neuroprotective potential of glucose-lowering drugs. The purpose was to directly compare the neuroprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) with different duration of action and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in type 2 diabetic rats with and without stroke. Methods: DM was modelled using high-fat diet and nicotinamide+streptozotocin protocol. The following groups (n = 15 each) were formed: DM without treatment, treatment with liraglutide, dulaglutide, canagliflozin as well as control group without DM and treatment. After 8 weeks, 10 rats from each group underwent middle cerebral artery occlusion. In the reperfusion period neurological deficit, neuroglial damage markers and brain necrosis were evaluated. Brain slices from the remaining 5 animals in each group were histologically examined for microglial activation and neuronal damage. Results: Brain damage was similar in “DM” and “Control” (17.53 [14.23; 26.58] and 15.87 [13.40; 22.68] % of total brain volume, respectively). All study drugs diminished damage volume comparing with “DM” and “Control” whereas the necrosis volume in “DM+Liraglutide” was smaller than in “DM+Canagliflozin” and did not significantly differ from “DM+Dulaglutide” (2.9 [1.83; 4.71], 6.17 [3.88; 8.88] and 4.57 [3.27; 7.90] %). The neurological deficit was more prominent in “DM” than in “Control”, while all the drugs demonstrated similar positive effect. Neurofilament light chains (NLC) did not differ between “DM” and “Control”. Dulaglutide and canagliflozin caused a marked decrease in NLC. Protein S100BB level was similar in “DM” and “Control”. Liraglutide caused the largest S100BB decrease, while canagliflozin did not influence it. In chronic brain ischaemia, all drugs increased the number of normal neurons, but GLP-1RAs had a more pronounced effect. DM was accompanied by increased number of activated microglial cells in Cornu Ammonis (CA)1 hippocampal region. Both GLP-1RAs reduced the number of Iba-1-positive cells, with dulaglutide being more effective than liraglutide, whereas canagliflozin did not affect this parameter. Conclusions: GLP-1RAs and SGLT-2i have neuroprotective properties against acute and chronic brain damage in diabetic rats, although the infarct-limiting effect of GLP-1RAs may be more pronounced. GLP-1RAs and SGLT-2i exert their protective effects by directly influencing neuronal survival, whereas GLP-1RAs also affect microglia.
- Open Access
- 1 January 2024
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 5 (3) , 64-71
The interplay of metabolically associated fatty liver disease and carbohydrate metabolism disorders: Current understanding of pathogenesis and treatment
Metabolic-associated fatty liver disease (MAFLD) is a chronic, non-infectious condition associated with metabolic disorders, including type 2 diabetes mellitus. This review describes current understanding of the MAFLD pathogenesis and its relationship to impaired carbohydrate metabolism, particularly the role of insulin resistance, dysregulated autophagy, and other factors contributing to disease development. Furthermore, it analyzes existing therapeutic approaches to MAFLD management, including the use of ursodeoxycholic acid as an autophagy modulator, as well as various glucose-lowering medications, such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and thiazolidinediones. Additionally, the pathogenetic role of fibroblast growth factor-21 in MAFLD development and the potential clinical application of FGF-21-based therapies are described. Thus, this overview reflects current knowledge regarding the pathogenesis and treatment of MAFLD, highlighting the necessity of a comprehensive approach to managing this condition in the context of its strong association with impaired carbohydrate metabolism
- 1 January 2024
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 5 (3) , 64-71
Open AccessThe interplay of metabolically associated fatty liver disease and carbohydrate metabolism disorders: Current understanding of pathogenesis and treatment
Metabolic-associated fatty liver disease (MAFLD) is a chronic, non-infectious condition associated with metabolic disorders, including type 2 diabetes mellitus. This review describes current understanding of the MAFLD pathogenesis and its relationship to impaired carbohydrate metabolism, particularly the role of insulin resistance, dysregulated autophagy, and other factors contributing to disease development. Furthermore, it analyzes existing therapeutic approaches to MAFLD management, including the use of ursodeoxycholic acid as an autophagy modulator, as well as various glucose-lowering medications, such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and thiazolidinediones. Additionally, the pathogenetic role of fibroblast growth factor-21 in MAFLD development and the potential clinical application of FGF-21-based therapies are described. Thus, this overview reflects current knowledge regarding the pathogenesis and treatment of MAFLD, highlighting the necessity of a comprehensive approach to managing this condition in the context of its strong association with impaired carbohydrate metabolism
- Open Access
- 3 November 2023
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 29 (6) , 579-592
Neuroprotective effects of glucose-lowering drugs in rat focal brain ischemia-reperfusion model
Background.Ischemic stroke is one of the leading causes of death in patients with type 2 diabetes mellitus (DM). According to the results of clinical and experimental studies, the ability of glucagon-like peptide-1 receptor agonists (GLP-1RA) to reduce the risk and severity of stroke in DM has been proven; data on the sodium-glucose cotransporter-2 inhibitors (SGLT-2i) effect are scarce. There has been no direct comparative study of the GLP-1RA and SGLT-2i neuroprotective effect.Objective.To evaluate and to compare the effect of GLP-1RA of varying duration of action and SGLT-2i of varying selectivity on the neurological deficit severity and the brain damage volume in a transient focal brain ischemia model in rats without DM.Design and methods.Male Wistar rats were divided into groups (n = 10 each) depending on the therapy received: “EMPA” (empagliflozin per os 2 mg/kg once daily), “CANA” (canagliflozin per os 25 mg/kg once daily), “LIRA” (liraglutide 1 mg/kg s. c. once daily), “DULA” (dulaglutide 0,12 mg/kg s. c. every 72 hours), “SEMA” (semaglutide 0,012 mg /kg s. c. once daily), “MET” (metformin per os 200 mg/kg once daily — comparison group), “Control” (administration of 0,9 % NaCl solution s. c. once daily). After 7 days, all groups underwent transient focal 30-minute filament middle cerebral artery occlusion. After 48 hours of reperfusion, neurological deficit was assessed using the Garcia scale, then the brain was collected and sections were stained with 1 % triphenyltetrazolium chloride solution to calculate the damage volume.Results.Neurological deficit severity in the “LIRA” (14,50 (12,25; 15,25) points) and “SEMA” (14,00 (13,50; 18,00) points) groups was significantly less than in the “Control” group (11.00 (6,75; 12,00) points). The use of both SGLT-2i, as well as metformin, had no effect on the neurological status. At the same time, therapy with all study drugs had an infarct-limiting effect, compared with the “Control” group (damage volume 24,50 (14,69; 30,12) % of the total brain volume). At the same time, the brain damage volume in the “MET” group (12,93 (6,65, 26,66) %) was greater than that in the “EMPA” (6,08 (2,97, 7,63) %), “CANA” (5,11 (3,96; 8,34) %), “LIRA” (3,40 (2,09; 8,08) %), “DULA” (4,37 (2,72; 5,40) %), “SEMA” (5,19 (4,11; 7,83) %) groups.Conclusions.SGLT-2i of varying selectivity and GLP-1RA of varying duration of action have a similar infarct-limiting effect in acute experimental brain ischemia. At the same time, GLP-1RA neuroprotective potential is higher, as it is characterized by an additional positive effect on the neurological status.
- 3 November 2023
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 29 (6) , 579-592
Open AccessNeuroprotective effects of glucose-lowering drugs in rat focal brain ischemia-reperfusion model
Background.Ischemic stroke is one of the leading causes of death in patients with type 2 diabetes mellitus (DM). According to the results of clinical and experimental studies, the ability of glucagon-like peptide-1 receptor agonists (GLP-1RA) to reduce the risk and severity of stroke in DM has been proven; data on the sodium-glucose cotransporter-2 inhibitors (SGLT-2i) effect are scarce. There has been no direct comparative study of the GLP-1RA and SGLT-2i neuroprotective effect.Objective.To evaluate and to compare the effect of GLP-1RA of varying duration of action and SGLT-2i of varying selectivity on the neurological deficit severity and the brain damage volume in a transient focal brain ischemia model in rats without DM.Design and methods.Male Wistar rats were divided into groups (n = 10 each) depending on the therapy received: “EMPA” (empagliflozin per os 2 mg/kg once daily), “CANA” (canagliflozin per os 25 mg/kg once daily), “LIRA” (liraglutide 1 mg/kg s. c. once daily), “DULA” (dulaglutide 0,12 mg/kg s. c. every 72 hours), “SEMA” (semaglutide 0,012 mg /kg s. c. once daily), “MET” (metformin per os 200 mg/kg once daily — comparison group), “Control” (administration of 0,9 % NaCl solution s. c. once daily). After 7 days, all groups underwent transient focal 30-minute filament middle cerebral artery occlusion. After 48 hours of reperfusion, neurological deficit was assessed using the Garcia scale, then the brain was collected and sections were stained with 1 % triphenyltetrazolium chloride solution to calculate the damage volume.Results.Neurological deficit severity in the “LIRA” (14,50 (12,25; 15,25) points) and “SEMA” (14,00 (13,50; 18,00) points) groups was significantly less than in the “Control” group (11.00 (6,75; 12,00) points). The use of both SGLT-2i, as well as metformin, had no effect on the neurological status. At the same time, therapy with all study drugs had an infarct-limiting effect, compared with the “Control” group (damage volume 24,50 (14,69; 30,12) % of the total brain volume). At the same time, the brain damage volume in the “MET” group (12,93 (6,65, 26,66) %) was greater than that in the “EMPA” (6,08 (2,97, 7,63) %), “CANA” (5,11 (3,96; 8,34) %), “LIRA” (3,40 (2,09; 8,08) %), “DULA” (4,37 (2,72; 5,40) %), “SEMA” (5,19 (4,11; 7,83) %) groups.Conclusions.SGLT-2i of varying selectivity and GLP-1RA of varying duration of action have a similar infarct-limiting effect in acute experimental brain ischemia. At the same time, GLP-1RA neuroprotective potential is higher, as it is characterized by an additional positive effect on the neurological status.
- Open Access
- 10 August 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 25 (4) , 247-252
Highly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation
Background. Chronic brain dyscirculation occurs in type 2 diabetes mellitus (DM2) with a high frequency and leads to patients disability. The early diagnosis of this disorder is difficult. Sodium-glucose cotransporter type 2 inhibitors are among the priority antidiabetic drugs due to their pronounced cardioprotective effect, but their effect on the central nervous system has not been studied enough. Aim. To study empagliflozin effect on clinical and laboratory parameters of brain damage in patients with DM2. Materials and methods. The study included patients with DM2 on metformin therapy (n=52). Patients with target glycated hemoglobin level formed the MET group (n=18), in those with non-target glycated hemoglobin level empagliflozin was added for 6 months (group MET+EMPA; n=19). A healthy control group was also created (n=15). The cognitive status and concentration of neurofilament light chains were studied. Results. In patients of the MET group, despite the target level of glycated hemoglobin, there was a cognitive deficit, according to the Montreal Cognitive Assessment: 25.0 (21.0; 27.0) points with a norm of 26 points or more. Therapy with empagliflozin led to the normalization of cognitive status after 6 months: 26.5 (24.0; 27.0) points. Initially, all patients had an increased neurofilament light chains level: 4.50 (3.31; 5.56) ng/ml in the MET group, 5.25 (3.75; 6.25) ng/ml in the MET+EMPA comparing with 3.50 (2.25; 3.50) ng/ml in the Control group. Empagliflozin therapy led to a decrease in this parameter after 3 months: 3.80 (3.25; 3.87) ng/ml and maintenance of this level after 6 months. Conclusion. DM2 is accompanied by pathological changes in the central nervous system even under satisfactory glycemic control. Empagliflozin therapy causes an improvement in cognitive status and a decrease in the level of neurofilament light chains.
- 10 August 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 25 (4) , 247-252
Open AccessHighly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation
Background. Chronic brain dyscirculation occurs in type 2 diabetes mellitus (DM2) with a high frequency and leads to patients disability. The early diagnosis of this disorder is difficult. Sodium-glucose cotransporter type 2 inhibitors are among the priority antidiabetic drugs due to their pronounced cardioprotective effect, but their effect on the central nervous system has not been studied enough. Aim. To study empagliflozin effect on clinical and laboratory parameters of brain damage in patients with DM2. Materials and methods. The study included patients with DM2 on metformin therapy (n=52). Patients with target glycated hemoglobin level formed the MET group (n=18), in those with non-target glycated hemoglobin level empagliflozin was added for 6 months (group MET+EMPA; n=19). A healthy control group was also created (n=15). The cognitive status and concentration of neurofilament light chains were studied. Results. In patients of the MET group, despite the target level of glycated hemoglobin, there was a cognitive deficit, according to the Montreal Cognitive Assessment: 25.0 (21.0; 27.0) points with a norm of 26 points or more. Therapy with empagliflozin led to the normalization of cognitive status after 6 months: 26.5 (24.0; 27.0) points. Initially, all patients had an increased neurofilament light chains level: 4.50 (3.31; 5.56) ng/ml in the MET group, 5.25 (3.75; 6.25) ng/ml in the MET+EMPA comparing with 3.50 (2.25; 3.50) ng/ml in the Control group. Empagliflozin therapy led to a decrease in this parameter after 3 months: 3.80 (3.25; 3.87) ng/ml and maintenance of this level after 6 months. Conclusion. DM2 is accompanied by pathological changes in the central nervous system even under satisfactory glycemic control. Empagliflozin therapy causes an improvement in cognitive status and a decrease in the level of neurofilament light chains.
- Open Access
- 14 July 2021
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 24 (2) , 111-121
Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
Background: Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having optimal cardioprotective properties. A comparative study of the various sodium-glucose co-transporter inhibitors representatives’ protective effects in experimental MI was not carried out within the framework of one study.Aim: To evaluate the influence of empagliflozin (EMPA) and canagliflozin (CANA), in comparison with sitagliptin (SITA), on hemodynamic parameters and myocardial damage area in rats with diabetes type 2 model in experimental MI.Materials and methods: Type 2 DM was modelled in Wistar rats by means of 4-week high-fat diet followed by nicotinamide 230 mg/kg and streptozotocin 60 mg/kg administration. 4 weeks after DM induction the following groups were made: «DM+SITA» — treatment with SITA 50 mg/kg, «DM+EMPA» — treatment with EMPA 2 mg/kg, «DM+CANA» — treatment with CANA 25 mg/kg per os once daily for 8 weeks. Animals in «DM» group remained untreated for the following 8 weeks. Rats in control group were fed with standard chow. 16 weeks after the experiment beginning transient global myocardial ischemia was modelled in all rats. Hemodynamic parameters and myocardium necrosis area were evaluated.Results: The necrosis area was larger in «DM» group, than in control one (p=0.018). Infarction size in «DM+SITA» did not differ from that in «DM» group (62.92(41.29;75.84) and 57.26(45.51;70.08)%, р=0.554). Necrosis area in «DM+EMPA» and «DM+CANA» groups was smaller than in «DM» group (37.90(20.76;54.66)%, 46.15(29.77;50.55) vs 57.26(45.51;70.08)%, р=0.008 and р=0.009, respectively). Necrosis size did not differ between «DM+EMPA» and «DM+CANA» groups (p=0.630). Ischemic contracture in «DM+CANA» group was less prominent than under the use of all other glucose-lowering drugs. We observed increase of coronary blood flow in «DM+EMPA» group, in comparison with «DM», «DM+CANA» and «DM+SITA» groups.Conclusions: SITA does not have cardioprotective effect in ischemia-reperfusion injury in diabetic rats. EMPA and CANA have similarly prominent infarct-limiting properties. EMPA is able to increase coronary blood flow, whereas cardioprotective action of CANA is associated with ischemic contracture diminishing.
- 14 July 2021
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 24 (2) , 111-121
Open AccessComparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
Background: Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having optimal cardioprotective properties. A comparative study of the various sodium-glucose co-transporter inhibitors representatives’ protective effects in experimental MI was not carried out within the framework of one study.Aim: To evaluate the influence of empagliflozin (EMPA) and canagliflozin (CANA), in comparison with sitagliptin (SITA), on hemodynamic parameters and myocardial damage area in rats with diabetes type 2 model in experimental MI.Materials and methods: Type 2 DM was modelled in Wistar rats by means of 4-week high-fat diet followed by nicotinamide 230 mg/kg and streptozotocin 60 mg/kg administration. 4 weeks after DM induction the following groups were made: «DM+SITA» — treatment with SITA 50 mg/kg, «DM+EMPA» — treatment with EMPA 2 mg/kg, «DM+CANA» — treatment with CANA 25 mg/kg per os once daily for 8 weeks. Animals in «DM» group remained untreated for the following 8 weeks. Rats in control group were fed with standard chow. 16 weeks after the experiment beginning transient global myocardial ischemia was modelled in all rats. Hemodynamic parameters and myocardium necrosis area were evaluated.Results: The necrosis area was larger in «DM» group, than in control one (p=0.018). Infarction size in «DM+SITA» did not differ from that in «DM» group (62.92(41.29;75.84) and 57.26(45.51;70.08)%, р=0.554). Necrosis area in «DM+EMPA» and «DM+CANA» groups was smaller than in «DM» group (37.90(20.76;54.66)%, 46.15(29.77;50.55) vs 57.26(45.51;70.08)%, р=0.008 and р=0.009, respectively). Necrosis size did not differ between «DM+EMPA» and «DM+CANA» groups (p=0.630). Ischemic contracture in «DM+CANA» group was less prominent than under the use of all other glucose-lowering drugs. We observed increase of coronary blood flow in «DM+EMPA» group, in comparison with «DM», «DM+CANA» and «DM+SITA» groups.Conclusions: SITA does not have cardioprotective effect in ischemia-reperfusion injury in diabetic rats. EMPA and CANA have similarly prominent infarct-limiting properties. EMPA is able to increase coronary blood flow, whereas cardioprotective action of CANA is associated with ischemic contracture diminishing.